Coherus BioSciences Announces Closing of Initial Public Offering and Exercise of Underwriters' Option to Purchase Additional Shares

KUALA LUMPUR, Nov 13 (Bernama) -- Coherus BioSciences, Inc. announced today the closing of its initial public offering of 6,803,702 shares of its common stock at a public offering price of $13.50 per share, before underwriting discounts, commissions and estimated expenses, which includes the purchase of 507,402 shares of Coherus common stock by the underwriters upon partial exercise of their option to purchase additional shares. All of the shares of common stock are being offered by Coherus. The Company's common stock is listed on The NASDAQ Global Market under the ticker symbol "CHRS". Coherus estimates net proceeds from the offering to be approximately $81.5 million, after deducting underwriting discounts and commissions and estimated offering expenses.

J.P. Morgan Securities LLC and Credit Suisse Securities (USA) LLC acted as joint book-running managers and Cowen and Company, LLC acted as lead manager for the offering.

For the full text, click here.